NHS, Donanemab and Alzheimer

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of its cost-effectiveness.
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a type of drug called a monoclonal antibody, which is given by infusion (through a drip in the arm).
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
Alzheimer’s drug donanemab for use in the country's national health service (NHS). The National Institute for Health and Care Excellence (NICE), which sets drug policy for the NHS, issued a draft guidance on Wednesday,
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...
Armed robbery in Revesby1d
Donanemab Approved for Early Alzheimer's in Adults
Donanemab works by removing a sticky protein called beta-amyloid from the brain that is believed to cause Alzheimer's disease, and in the trials ...
Second ‘game-changing’ Alzheimer’s drug donanemab gets green light in UK – but WON’T be available on NHS
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
The Pharma Letter1d
Second Alzheimer’s drug, donanemab, rejected for NHS use
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...
ITV1d
Alzheimer’s drug rejected for NHS use: What is Donanemab?
This comes as the Medicines and Healthcare Products Regulatory Agency (MHRA) said in August the drug, Donanemab, manufactured by pharmaceutical giant Eli Lilly, could be licensed for use in the UK.
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
Lilly’s Kisunla does not demonstrate “good value” for UK’s NHS
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.